In view of these findings, it appears that resistin and IL-6 may serve as novel, mechanistically-linked set of serum biomarkers exhibiting greater incidence as well as overall levels in AA BC patients compared to that in their CA counterparts. This evidence concerns the gene RETN and breast cancer.